

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

Prot. n°			Patologia	Titolo	osservazionale o sperimentale	profit / no profit
31	/	18	NEUROENDOCRINO	Impatto sull'outcome clinico dell'impiego degli Analoghi della Somatostatina (SSA) in combinazione a Peptide Receptor Radionuclide Therapy (PRRT) vs PRRT esclusiva, nei tumori neuroendocrini ben differenziati, avanzati	O	NP
220	/	19	NEUROENDOCRINO	ENETS - REGISTRY	O	NP
240	/	19	NET	Studio di fase II finalizzato a valutare il profilo di sicurezza e di attività di cabozantinib in combinazione a lanreotide in tumori neuroendocrini (NET) gastroenteropancreatici (GEP) e toracici (LOLA trial).	S	NP
243	/	19	NET	A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET	S	P
299	/	20	NET	InterNaTional rEgistry oN Sars-cov-2 positiVe nEuroendocrine neoplasm patients	O	NP
177	/	14	PANCREAS-VIE BILIARI	Identificazione delle cellule tumorali circolanti e dei livelli di ctDNA nel sangue dei pazienti affetti	O	NP
118	/	17	PANCREAS-VIE BILIARI	Studio GARIBALDI: Valutazione dell'applicazione delle Linee Guida nella pratica medica in Italia. Studio osservazionale multicentrico per il trattamento adiuvante e di prima linea di pazienti con adenocarcinoma duttale del pancreas	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

72	/	19	PANCREAS-VIE BILIARI	"Studio multicentrico di Fase 3, in aperto, randomizzato, con controllo attivo per valutare l'efficacia e la sicurezza di pemigatinib rispetto a gemcitabina più chemioterapia a base di cisplatino nel trattamento di prima linea di partecipanti affetti da colangiocarcinoma non resecabile o metastatico con riarrangiamento di FGFR2 (FIGHT-302)"-	S	P
105	/	19	PANCREAS-VIE BILIARI	Studio Osservazionale sulla fattibilità e l'utilità' di un'estesa caratterizzazione molecolare tramite Foundationone CDX in pazienti affetti da carcinomi biliopancreatici. NO PROFIT	O	NP
96	/	21	PANCREAS-VIE BILIARI	Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)"	S	NP
225	/	21	PANCREAS-VIE BILIARI	A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)	S	P
113	/	21	PANCREAS-VIE BILIARI	STUDIO OSSERVAZIONALE SULL'IMPATTO PROGNOSTICO/PREDITTIVO DELLE ALTERAZIONI DEI GENI DEL DNA REPAIR SUI TUMORI BILIOPANCREATICI	O	NP
04	/	15	GASTRO-ENTERICO	Studio prospettico per la determinazione del profilo molecolare di resistenza alle "terapie target" in pazienti con tumori solidi – protocollo profiling-CANDIOLO	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

117	/	15	GASTRO-ENTERICO	Valutazione esplorativa di nuovi potenziali fattori prognostici in pazienti affetti da carcinomi gastrointestinali	O	NP
120	/	15	GASTRO-ENTERICO	Studio multicentrico traslazionale per la determinazione del profilo genomico dei carcinomi a primitività sconosciuta (CUP). De braud	O	NP
103	/	16	GASTRO-ENTERICO	Assessment of Ramucirumab plus paclitaxel as switch MANTelnance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III Trial	S	NP
205	/	17	GASTRO-ENTERICO	Studio AMNESIA: Studio italiano osservazionale multicentrico sui meccanismi molecolari di resistenza al Trastuzumab in tumori dello stomaco o della giunzione gastro-esofagea (GGE) HER-2 positivi	O	NP
16	/	18	GASTRO-ENTERICO	PERISCOPE: studio di fase II multicentrico di chemioterapia perioperatoria nel cancro gastrico operabile	S	NP
36	/	18	GASTRO-ENTERICO	ADJUVANT CAPECITABINE IN HIGH RISK PSEUDOMYXOMA PERITONEI PATIENTS TREATED WITH CYTOREDUCTIVE SURGERY (CRS) AND HYPERTERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)	S	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

163	/	18	GASTRO-ENTERICO	NO PROFIT. Titolo PEMBROLIZUMAB IN PAZIENTI CON CANCRO DEL COLON RETTO METASTATICO CON SISTEMA DI "MISMATCH REPAIR" INTATTO DOPO INDUZIONE FARMACOLOGICA DI IPERMUTABILITÀ	S	NP
54	/	19	COLON	CLASSIFICAZIONE DEL RISCHIO DI RIPRESA DI MALATTIA ATTRAVERSO LO STUDIO DEL PROFILO METABOLOMICO E DEL DNA TUMORALE CIRCOLANTE (ctDNA) IN PAZIENTI CON TUMORI DEL COLON IN STADIO INIZIALE. no profit	O	NP
174	/	19	COLON	NO-PROFIT. A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting	S	NP
136	/	19	COLON	A master protocol empowering Precision Research in Colorectal Cancer. NO -PROFIT	O	NP
35	/	20	COLON	"A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)."	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

204	/	20	ESOFAGO	RANDOMIZED PHASE II STUDY OF PANITUMUMAB RECHALLENGE FOLLOWED BY REGORAFENIB versus THE REVERSE SEQUENCE IN RAS AND BRAF WILD-TYPE CHEMOREFRACTORY METASTATIC COLORECTAL CANCER PATIENTS	S	NP
151	/	20	COLON	tudio di Fase 1b con la combinazione 5-fluorouracile, leucovorin, irinotecano e temozolomide (FLIRT) in associazione a bevacizumab come trattamento di prima linea in pazienti con carcinoma del colon-retto metastatico con stabilità dei microsatelliti e silenziamento di MGMT	S	NP
289	/	20	COLON	A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Doseexpansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03	S	P
293	/	20	GASTRO-ENTERICO	Tremellmumab aNd durvalumab combination For the non-operative management (NOM) of Microsatellite Instability (MSI)-high resectable gastric or gastroesophageal junction cancer:The multicentre, single-arm, multi-cohort, Phase II INFINITY study.	S	NP
128	/	21	GASTRO-ENTERICO	A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

276	/	20	COLON	RETROSPECTIVE OBSERVATIONAL STUDY ON THE USE OF IMMUNOTHERAPY WITH ANTI PD-1 ANTIBODIES IN PATIENTS WITH MSI-H METASTATIC COLORECTAL CANCER - GOIRC-07-2019 (CA209-7TL)"	O	NP
125	/	21	COLON	"A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)"	S	P
61	/	21	ANO	Clinical Protocol CA2099N9A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers	S	P
149	/	21	COLON	Studio di fase III randomizzato volto a valutare l'efficacia e la sicurezza di Lenvatinib (E7080/MK-7902) più Pembrolizumab (MK-3475) più chemioterapia rispetto alla terapia assistenziale standard come trattamento di prima linea nei partecipanti con adenocarcinoma gastroesofageo avanzato/metastatico (LEAP-015)	S	P
124	/	21	GASTRO-ENTERICO	Studio di fase 3, multicentrico, in aperto, randomizzato a due bracci di trastuzumab deruxtecan in soggetti con adenocarcinoma gastrico o della giunzione gastro-esofagea (GGE) HER2 positivo, metastatico e/o non resecabile che hanno manifestato una progressione durante o dopo un regime contenente trastuzumab (DESTINY-Gastric04)	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

65	/	21	GASTRO-ENTERICO	"Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in Liquid Blospy to compare in first-line therapy FOLFIRI plus CetuximAb or BevacizumaB (LIBImAb Study)"	S	NP
188	/	21	COLON	"Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC trial"	S	NP
201	/	21	COLON	AN OPEN-LABEL, SINGLE-ARM, PHASE IB/IIA TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF THE EP4 RECEPTOR ANTAGONIST CR6086 IN COMBINATION WITH THE PD-1 INHIBITOR BALSTILIMAB (AGEN2034), IN PATIENTS WITH PRETREATED MISMATCH-REPAIR-PROFICIENT AND MICROSATELLITE STABLE METASTATIC COLORECTAL CANCER."	S	P
202	/	21	COLON	"A phase 1/2 study exploring the safety and activity of trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients"	S	P
173	/	21	COLON	Protocol Title:A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

176	/	21	ESOFAGO	"Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer: the ShorTrip study"	S	NP
216	/	21	COLON	Studio prospettico per l'investigazione della biologia tumorale e dei fattori di resistenza alle terapie mediante biopsia liquida e patient derived organoids (PDO) in pazienti con tumori del tratto gastroenterico, bilio-pancreatico, tumori neuroendocrini e carcinomi a cellule di Merkel"	O	NP
140	/	21	GASTRO-ENTERICO	ItaLynch: mainstreaming the diagnosis of Lynch Syndrome	O	NP
03	/	21	GASTRO-ENTERICO	Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study	S	NP
262	/	21	COLON	A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with pembrolizumab or cetuximab for the treatment of participants with advanced and metastatic colorectal cancer"	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

38	/	22	COLON	"A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation"	S	P
22	/	22	COLON	"A PHASE 2/3 STUDY OF ALX148 IN PATIENTS WITH ADVANCED HER2-OVEREXPRESSING GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (ASPEN-06)"	S	P
231	/	21	GASTRO-ENTERICO	Studio osservazionale sulle caratteristiche cliniche ed anatomopatologiche e sugli outcome dei pazienti affetti da carcinomi gastrointestinali e neoplasie neuroendocrine afferenti all'Istituto Nazionale dei Tumori di Milano.	O	NP
144	/	15	T. UROGENITALE (RENE-PROSTATA)	Banca Dati Metastasi Ossee	O	NP
71	/	18	T. UROGENITALE (RENE-PROSTATA)	indagare fattori predittivi di risposta in pazienti affetti da carcinoma renale metastatico (mRCC) trattati con Nivolumab (studio I-RENE)	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

147	/	18	T. UROGENITALE (RENE-PROSTATA)	BIORENE (No profit osservazionale BIOLOGICO prospettico) Studio prospettico traslazionale volto ad indagare fattori prognostici e predittivi di risposta o resistenza ai trattamenti in pazienti affetti da carcinoma renale metastatico (mRCC)	O	NP
107	/	18	T. UROGENITALE (RENE-PROSTATA)	ACACIA (No profit con farmaco) Studio multicentrico, randomizzato, in aperto di fase III volto a valutare l'attività di chemioterapia adiuvante versus osservazione/mitotane dopo chirurgia di prima linea in pazienti affetti da carcinoma corticosurrenale localizzato ad alto rischio di recidiva	S	NP
228	/	19	T. UROGENITALE (RENE-PROSTATA)	Studio osservazionale retrospettivo sulla sicurezza di Nivolumab nei Pazienti con Carcinoma Renale Metastatico ed Insufficienza Renale	O	NP
164	/	18	T. UROGENITALE (RENE-PROSTATA)	Meet-URO 4 - Studio multicentrico randomizzato di fase III: Docetaxel vs ormonoterapia come trattamento di seconda linea in pazienti asintomatici o oligosintomatici con tumore della prostata metastatico, resistente alla castrazione, in progressione dopo terapia con abiraterone o enzalutamide. (Non-Profit)	S	NP
175	/	20	T. UROGENITALE (RENE-PROSTATA)	Osteonecrosi della mandibola in pazienti affetti da carcinoma renale con metastasi ossee. Studio retrospettivo multicentrico (studio REBONE)	O	NP
5	/	21	T. UROGENITALE (RENE-PROSTATA)	A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC).	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

135	/	21	T. UROGENITALE (RENE-PROSTATA)	Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients".	O	P
89	/	21	T. UROGENITALE (RENE-PROSTATA)	KATY:Studio Osservazionale prospettico biologico/retrospetivo (raccolta campioni biologici)	O	NP
103	/	21	T. UROGENITALE (RENE-PROSTATA)	An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)	S	P
04	/	22	T. UROGENITALE (RENE-PROSTATA)	A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy (MK-6482-022)	S	P
35	/	21	T. UROGENITALE (RENE-PROSTATA)	An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy	S	P
17	/	18	UROTELIO- TESTICOLO- GERMINALI	A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

179	/	18	UROTELIO-TESTICOLO-GERMINALI	STUDIO CLINICO DI FASE 3, RANDOMIZZATO, CONTROLLATO CON PRODOTTO DI CONFRONTO PER STUDIARE L'EFFICACIA E LA SICUREZZA DI PEMBROLIZUMAB (MK-3475) IN COMBINAZIONE CON BACILLO DI CALMETTE –GUERIN (BCG) IN SOGGETTI AFFETTI DA TUMORE DELLA VESCICA NON-MUSCOLO INVASIVO AD ALTO RISCHIO (HR NMIBC) CHE E' PERSISTENTE O RICORRENTE DOPO INDUZIONE CON BCG.	S	NP
180	/	18	UROTELIO-TESTICOLO-GERMINALI	Cabozantinib plus durvalumab (Medi 4736) in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histology: an open-label, single-centre, phase 2, single-arm proof-of-concept trial-ARCADIA	S	NP
158	/	18	UROTELIO-TESTICOLO-GERMINALI	A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer	S	P
94	/	19	UROTELIO-TESTICOLO-GERMINALI	Studio Randomizzato di fase III su Pembrolizumab Perioperatorio più Cistectomia versus Cistectomia in pazienti Cisplatino-elegibili affetti da carcinoma della vescica muscolo-invasivo (KEYNOTE-905)"	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

3	/	20	UROTELIO-TESTICOLO-GERMINALI	Studio clinico di fase 3, randomizzato, in doppio cieco, controllato con placebo per studiare l'efficacia e la sicurezza di Pembrolizumab (MK-3475) in combinazione con la Chemioradioterapia (CRT) versus la sola Chemioradioterapia in soggetti con tumore alla vescica muscolo-invasivo (MIBC) (KEYNOTE-992)	S	P
16	/	20	UROTELIO-TESTICOLO-GERMINALI	A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions Protocol 42756493BLC2003; Phase 2	S	P
45	/	18	POLMONE	Exploiting metformin plus/minus cyclic Fasting Mimicking Diet (FMD) to improve the efficacy of first line chemo-immunotherapy in advanced LKB1-inactive lung adenocarcinoma	O	NP
146	/	15	POLMONE	PROGETTO TIMOMA: CREAIONE DI UN DATABASE GENETICO E CLINICO PER LO STUDIO DELLE NEOPLASIE EPITELIALI TIMICHE	O	NP
08	/	18	POLMONE	A mobile supportive care app for patients with metastatic lung cancer: a pilot randomized controlled trial (NO-PROFIT)	O	NP
23	/	18	POLMONE	NO-PROFIT_Miglioramento delle strategie di trattamento nei tumori epiteliali del timo: un impegno congiunto del TYME Studio RELEVANT.	S/O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

136	/	18	POLMONE	A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)	S	P
212	/	18	POLMONE	A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants	S	P
119	/	19	POLMONE	Uno studio multicentrico randomizzato di fase III che mette a confronto atezolizumab più bevacizumab e la chemioterapia standard rispetto a bevacizumab e la chemioterapia standard come trattamento di prima linea per il mesotelioma pleurico maligno di stadio avanzato. no profit	S	NP
196	/	19	POLMONE	TRIDENT -1A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)	S	P
235	/	19	POLMONE	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer	S	p

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

237	/	19	POLMONE	Studio randomizzato, in aperto, di fase 3, di SAR408701 rispetto a Docetaxel in pazienti con neoplasia polmonare metastatica già trattata non a piccole cellule e a cellule non squamose con tumori positivi a CEACAM5	S	P
37	/	18	POLMONE	MILES 5 : A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC.	S	NP
182	/	20	POLMONE	BLU 667 : A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer	S	P
259	/	20	POLMONE	GSK213400 INT 259/20 "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB or IV Non-Small Cell Lung Cancer"	S	P
60	/	21	POLMONE	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)	S	p

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

291	/	20	POLMONE	A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)	S	P
59	/	21	POLMONE	BRIDGE trial: Phase II trial of durvalumaB and chemotheRapy Induction followed by Durvalumab and radiotherapy in larGe volume stage III NSCLC	S	NP
104	/	21	POLMONE	A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung	S	P
175	/	21	POLMONE	Studio di fase 2, non randomizzato, in aperto, multicoorte, multicentrico per valutare il beneficio clinico di SAR444245 (THOR-707) in combinazione con altre terapie antitumorali per il trattamento di pazienti con carcinoma polmonare o mesotelioma pleurico	S	P
108	/	20	POLMONE	TAK-788-3001 A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

197	/	21	POLMONE	A RANDOMIZED PHASE 3 STUDY OF MRTX849 VERSUS DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION	S	P
248	/	21	POLMONE	A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy (MERMAID-2)	S	P
23	/	22	POLMONE	A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer	S	P
228	/	20	MELANOMA	Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients	S	P
261	/	20	MELANOMA	A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

71	/	21	MELANOMA	Studio osservazionale, retrospettivo-prospettico volto all'individuazione di nuovi fattori prognostici e predittivi in pazienti affetti da melanoma sottoposti a terapia antitumorale	O	NP
262	/	20	MELANOMA	Studio di fase II, randomizzato, non-comparativo, sulla terapia neoadiuvante più adiuvante con combinazione o sequenza di vemurafenib, cobimetinib e atezolizumab in pazienti con melanoma ad alto rischio, asportabile chirurgicamente con mutazione BRAF o wild type	S	NP
57	/	21	MELANOMA	A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D	S	P
13	/	21	MELANOMA	Retrospective-prospective observational study of Italian patients treated in melanoma adjuvant cohort MAP to evaluate relapse free survival and overall survival –MADAM (Maximing ADjuvAnt MAP)	O	P
138	/	19	MELANOMA	(SKYNTOX - Observational study on skin toxicity by oncological therapies)	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

194	/	21	MELANOMA	A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab-Nivolumab Fixed-dose Combination (BMS-986213) versus Nivolumab after Complete Resection of Stage III-IV Melanoma	S	P
62	/	22	MELANOMA	A Phase I, open-label, dose escalation study of oral LGK974 in patients with malignancies dependent on Wnt ligands	S	P
243	/	21	MELANOMA	A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with BRAF V600E/K Mutation-Positive Metastatic or unresectable locally advanced Melanoma	S	P
36	/	22	MELANOMA	A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]1 Therapy - ARTISTRY-6	S	P
15	/	22	MELANOMA	Registro Clinico Nazionale sul Melanoma II	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

155	/	18	TUMORI SOLIDI	“Studio di fase 1 con aumento progressivo della dose e ampliamento delle coorti, per la valutazione di TSR-042, un anticorpo monoclonale anti-PD-1, in pazienti affetti da tumori solidi in stadio avanzato” - N. protocollo: 4010-01-001	S	P
63	/	18	TUMORI SOLIDI	Studio di fase 1/2 su LOXO-292 Orale in pazienti con tumori solidi avanzati, che include tumori solidi positivi con fusione di RET, carcinoma midollare della tiroide e altri tumori con attivazione RET (LIBRETTO-001).	S	P
89	/	19	TUMORI SOLIDI	Studio multicentrico, di fase 1/2, in aperto per valutare la sicurezza e l'efficacia di KY1044 come agente singolo e in combinazione con anti-PD-L1 (atezolizumab) in pazienti adulti con tumori maligni selezionati in stadio avanzato	S	P
169	/	19	TUMORI SOLIDI	A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors	S	P
36	/	20	TUMORI SOLIDI	Studio di Fase I/Ib, in aperto, multicentrico, con KAZ954 in monoterapia e in associazione a Spatalizumab, NZV930 e NIR178 in pazienti con tumori solidi in stadio avanzato	S	P
180	/	20	TUMORI SOLIDI	Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

56	/	21	TUMORI SOLIDI	A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation	S	P
193	/	21	TUMORI SOLIDI	A PHASE I/IIb GLOBAL, MULTICENTER, OPEN-LABEL UMBRELLA STUDY EVALUATING THE SAFETY AND EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH METASTATIC COLORECTAL CANCER	S	P
191	/	21	TUMORI SOLIDI	Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor2 Overexpression (HER2+)(DESTINY-Lung03)	S	P
222	/	21	POLMONE	A Phase I/IIb, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2α stabilizing mutations	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

21	/	17	TUMORI SOLIDI	CMAK683X2101 A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies	S	P
5	/	22	TUMORI SOLIDI	A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors	S	P
60	/	22	TUMORI SOLIDI	A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TALETRECTINIB IN PATIENTS WITH ADVANCED OR METASTATIC ROS1 POSITIVE NSCLC AND OTHER SOLID TUMORS	S	P
241	/	21	TUMORI SOLIDI	"An open-label, Phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics and efficacy of the Aryl Hydrocarbon Receptor inhibitor (AhRi) BAY 2416964 in combination with pembrolizumab in participants with advanced solid tumors"	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

66	/	21	TUMORI SOLIDI	TUMOR-AGNOSTIC PRECISION IMMUNO-ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU(TAPISTRY)PHASE IIPLATFORM TRIAL	S	P
151	/	15	TUMORI SOLIDI	STUDIO OSSERVAZIONALE VOLTO A VALUTARE L'IMPATTO PROGNOSTICO DI FATTORI LEGATI ALL'IMMUNITA' IN PAZIENTI AFFETTI DA NEOPLASIE TRATTATE CON IMMUNOTERAPIA	O	NP
192	/	21	TUMORI SOLIDI	Basket ofBaskets: A Modular, Open-label, Phase II, Multicentre Study ToEvaluateTargeted Agents in Molecularly Selected PopulationsWith Advanced Solid Tumours.	S	NP
200	/	20	C.MAMMARIO	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-0077 PLUS PALBOCICLIB AND FULVESTRANT VERSUS PLACEBO PLUS PALBOCICLIB AND FULVESTRANT IN PATIENTS WITH PIK3CA-MUTANT, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER	S	P
196	/	20	C.MAMMARIO	A Master Protocol Empowering Mechanobiology TranslationalResearch in BreastCancer	O	NP

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

127	/	21	C.MAMMARIO	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY	S	P
138	/	21	C.MAMMARIO	Observational study of effectiveness and safety of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and anti-HER2 target therapy"	O	NP
221	/	21	C.MAMMARIO	EPIK-B5: Studio di Fase III, randomizzato, in doppio cieco, controllato versus placebo, con alpelisib (BYL719) in associazione a fulvestrant negli uomini e nelle donne in post-menopausa con carcinoma mammario in stadio avanzato HR-positivo, HER2-negativo con mutazione PIK3CA, che ha manifestato progressione durante o dopo inibitore dell'aromatasi e inibitore di CDK4/6	S	P
283	/	20	C.MAMMARIO	EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation	S	P

STUDI ATTIVI AL RECLUTAMENTO S.C. OM1

08	/	12	TUMORI SOLIDI	evaluate efficacy and safety of ribociclib with endocrine	O	NP
31	/	19	DIETA	Efficacy of metfOrmin in PrevenTIng glucocorticoid-induced diabetes in Melanoma, breAst or Lung cancer patients with brain metastases: the phase II OPTIMAL study	S	NP
157		17	DIETA	Impact of Dietary Intervention on tumor immunity: The DigesT trial	S	NP